Sustained release emphasizing recombinant human bone morphogenetic protein-2

Bone homeostasis is a dynamic process involving a myriad of cells and substrates modulated by regulatory signals such as hormones, growth and differentiating factors. When this environment is damaged, the regenerative sequalae follows a programmed pattern, and the capacity for successful recovery is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced drug delivery reviews 1998-05, Vol.31 (3), p.303-318
Hauptverfasser: Winn, Shelley R, Uludag, Hasan, Hollinger, Jeffrey O
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 318
container_issue 3
container_start_page 303
container_title Advanced drug delivery reviews
container_volume 31
creator Winn, Shelley R
Uludag, Hasan
Hollinger, Jeffrey O
description Bone homeostasis is a dynamic process involving a myriad of cells and substrates modulated by regulatory signals such as hormones, growth and differentiating factors. When this environment is damaged, the regenerative sequalae follows a programmed pattern, and the capacity for successful recovery is often dependent on the extent of the injury. Many bony deficits that are excessively traumatic will not result in complete recovery and require therapeutic intervention(s) such as autografting or grafting from banked bone. However, for numerous reasons, an unacceptably high rate of failure is associated with these conventional therapies. Thus, alternative approaches are under investigation. A class of osteogenic regulatory molecules, the bone morphogenetic proteins (BMPs), have been isolated, cloned and characterized as potent supplements to augment bone regeneration. Optimizing a therapeutic application for BMPs may be dependent upon localized sustained release which in kind relies on a safe and well characterized carrier system. This review will discuss the current status of BMPs in bone regeneration and specifically will present the potential for a clinical therapeutic role of recombinant human BMP-2 sustained release carrier systems.
doi_str_mv 10.1016/S0169-409X(97)00126-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_33485149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X97001269</els_id><sourcerecordid>1859323639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-59edae63c7dff4243dc7946a261450b8ba89cc7c501eadfe0daf3defb0b282193</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMoun78BKUnWQ_VfLVJTiKLX7DgYRW8hTSZupFtujatoL_e1op4ci8zMDwzL8yD0DHB5wST_GLRF5VyrJ6nSpxhTGieqi00IVLQVFLFt9HkF9lD-zG-DpDI8S7aI1gykTMyQfNFF1vjA7ikgRWYCAlU66WJ_tOHl35m66rwwYQ2WXaVCUlRB0iqulkv6xcI0HqbrJu6BR9Seoh2SrOKcPTTD9DTzfXj7C6dP9zez67mqeWKtGmmwBnImRWuLDnlzFmheG5oTniGC1kYqawVNsMEjCsBO1MyB2WBCyopUewAnY53--S3DmKrKx8trFYmQN1FzRiXGeGbQUpYlkkqenD6L0hkphhlORtuZiNqmzrGBkq9bnxlmg9NsB7U6G81evi7VkJ_q9HD3slPRFdU4P5sjS564HIEoH_du4dGR-shWHC-19BqV_sNEV_hZp9z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859323639</pqid></control><display><type>article</type><title>Sustained release emphasizing recombinant human bone morphogenetic protein-2</title><source>Access via ScienceDirect (Elsevier)</source><creator>Winn, Shelley R ; Uludag, Hasan ; Hollinger, Jeffrey O</creator><creatorcontrib>Winn, Shelley R ; Uludag, Hasan ; Hollinger, Jeffrey O</creatorcontrib><description>Bone homeostasis is a dynamic process involving a myriad of cells and substrates modulated by regulatory signals such as hormones, growth and differentiating factors. When this environment is damaged, the regenerative sequalae follows a programmed pattern, and the capacity for successful recovery is often dependent on the extent of the injury. Many bony deficits that are excessively traumatic will not result in complete recovery and require therapeutic intervention(s) such as autografting or grafting from banked bone. However, for numerous reasons, an unacceptably high rate of failure is associated with these conventional therapies. Thus, alternative approaches are under investigation. A class of osteogenic regulatory molecules, the bone morphogenetic proteins (BMPs), have been isolated, cloned and characterized as potent supplements to augment bone regeneration. Optimizing a therapeutic application for BMPs may be dependent upon localized sustained release which in kind relies on a safe and well characterized carrier system. This review will discuss the current status of BMPs in bone regeneration and specifically will present the potential for a clinical therapeutic role of recombinant human BMP-2 sustained release carrier systems.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/S0169-409X(97)00126-9</identifier><identifier>PMID: 10837631</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Bone ; Bone regeneration ; Cloning ; Collagen ; Growth factors ; Hormones ; Organic acids ; Osteoconduction ; Osteoinduction ; Poly(α-hydroxy acids) ; Proteins ; rhBMP-2 ; TGF-β superfamily ; Tissue engineering</subject><ispartof>Advanced drug delivery reviews, 1998-05, Vol.31 (3), p.303-318</ispartof><rights>1998 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-59edae63c7dff4243dc7946a261450b8ba89cc7c501eadfe0daf3defb0b282193</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0169-409X(97)00126-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10837631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Winn, Shelley R</creatorcontrib><creatorcontrib>Uludag, Hasan</creatorcontrib><creatorcontrib>Hollinger, Jeffrey O</creatorcontrib><title>Sustained release emphasizing recombinant human bone morphogenetic protein-2</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>Bone homeostasis is a dynamic process involving a myriad of cells and substrates modulated by regulatory signals such as hormones, growth and differentiating factors. When this environment is damaged, the regenerative sequalae follows a programmed pattern, and the capacity for successful recovery is often dependent on the extent of the injury. Many bony deficits that are excessively traumatic will not result in complete recovery and require therapeutic intervention(s) such as autografting or grafting from banked bone. However, for numerous reasons, an unacceptably high rate of failure is associated with these conventional therapies. Thus, alternative approaches are under investigation. A class of osteogenic regulatory molecules, the bone morphogenetic proteins (BMPs), have been isolated, cloned and characterized as potent supplements to augment bone regeneration. Optimizing a therapeutic application for BMPs may be dependent upon localized sustained release which in kind relies on a safe and well characterized carrier system. This review will discuss the current status of BMPs in bone regeneration and specifically will present the potential for a clinical therapeutic role of recombinant human BMP-2 sustained release carrier systems.</description><subject>Bone</subject><subject>Bone regeneration</subject><subject>Cloning</subject><subject>Collagen</subject><subject>Growth factors</subject><subject>Hormones</subject><subject>Organic acids</subject><subject>Osteoconduction</subject><subject>Osteoinduction</subject><subject>Poly(α-hydroxy acids)</subject><subject>Proteins</subject><subject>rhBMP-2</subject><subject>TGF-β superfamily</subject><subject>Tissue engineering</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkU1LxDAQhoMoun78BKUnWQ_VfLVJTiKLX7DgYRW8hTSZupFtujatoL_e1op4ci8zMDwzL8yD0DHB5wST_GLRF5VyrJ6nSpxhTGieqi00IVLQVFLFt9HkF9lD-zG-DpDI8S7aI1gykTMyQfNFF1vjA7ikgRWYCAlU66WJ_tOHl35m66rwwYQ2WXaVCUlRB0iqulkv6xcI0HqbrJu6BR9Seoh2SrOKcPTTD9DTzfXj7C6dP9zez67mqeWKtGmmwBnImRWuLDnlzFmheG5oTniGC1kYqawVNsMEjCsBO1MyB2WBCyopUewAnY53--S3DmKrKx8trFYmQN1FzRiXGeGbQUpYlkkqenD6L0hkphhlORtuZiNqmzrGBkq9bnxlmg9NsB7U6G81evi7VkJ_q9HD3slPRFdU4P5sjS564HIEoH_du4dGR-shWHC-19BqV_sNEV_hZp9z</recordid><startdate>19980504</startdate><enddate>19980504</enddate><creator>Winn, Shelley R</creator><creator>Uludag, Hasan</creator><creator>Hollinger, Jeffrey O</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U5</scope><scope>8FD</scope><scope>L7M</scope></search><sort><creationdate>19980504</creationdate><title>Sustained release emphasizing recombinant human bone morphogenetic protein-2</title><author>Winn, Shelley R ; Uludag, Hasan ; Hollinger, Jeffrey O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-59edae63c7dff4243dc7946a261450b8ba89cc7c501eadfe0daf3defb0b282193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Bone</topic><topic>Bone regeneration</topic><topic>Cloning</topic><topic>Collagen</topic><topic>Growth factors</topic><topic>Hormones</topic><topic>Organic acids</topic><topic>Osteoconduction</topic><topic>Osteoinduction</topic><topic>Poly(α-hydroxy acids)</topic><topic>Proteins</topic><topic>rhBMP-2</topic><topic>TGF-β superfamily</topic><topic>Tissue engineering</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Winn, Shelley R</creatorcontrib><creatorcontrib>Uludag, Hasan</creatorcontrib><creatorcontrib>Hollinger, Jeffrey O</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Winn, Shelley R</au><au>Uludag, Hasan</au><au>Hollinger, Jeffrey O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained release emphasizing recombinant human bone morphogenetic protein-2</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>1998-05-04</date><risdate>1998</risdate><volume>31</volume><issue>3</issue><spage>303</spage><epage>318</epage><pages>303-318</pages><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>Bone homeostasis is a dynamic process involving a myriad of cells and substrates modulated by regulatory signals such as hormones, growth and differentiating factors. When this environment is damaged, the regenerative sequalae follows a programmed pattern, and the capacity for successful recovery is often dependent on the extent of the injury. Many bony deficits that are excessively traumatic will not result in complete recovery and require therapeutic intervention(s) such as autografting or grafting from banked bone. However, for numerous reasons, an unacceptably high rate of failure is associated with these conventional therapies. Thus, alternative approaches are under investigation. A class of osteogenic regulatory molecules, the bone morphogenetic proteins (BMPs), have been isolated, cloned and characterized as potent supplements to augment bone regeneration. Optimizing a therapeutic application for BMPs may be dependent upon localized sustained release which in kind relies on a safe and well characterized carrier system. This review will discuss the current status of BMPs in bone regeneration and specifically will present the potential for a clinical therapeutic role of recombinant human BMP-2 sustained release carrier systems.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>10837631</pmid><doi>10.1016/S0169-409X(97)00126-9</doi><tpages>16</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0169-409X
ispartof Advanced drug delivery reviews, 1998-05, Vol.31 (3), p.303-318
issn 0169-409X
1872-8294
language eng
recordid cdi_proquest_miscellaneous_33485149
source Access via ScienceDirect (Elsevier)
subjects Bone
Bone regeneration
Cloning
Collagen
Growth factors
Hormones
Organic acids
Osteoconduction
Osteoinduction
Poly(α-hydroxy acids)
Proteins
rhBMP-2
TGF-β superfamily
Tissue engineering
title Sustained release emphasizing recombinant human bone morphogenetic protein-2
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A30%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20release%20emphasizing%20recombinant%20human%20bone%20morphogenetic%20protein-2&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Winn,%20Shelley%20R&rft.date=1998-05-04&rft.volume=31&rft.issue=3&rft.spage=303&rft.epage=318&rft.pages=303-318&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/S0169-409X(97)00126-9&rft_dat=%3Cproquest_cross%3E1859323639%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859323639&rft_id=info:pmid/10837631&rft_els_id=S0169409X97001269&rfr_iscdi=true